COMPARE · Data as of October 9, 2026

ELV vs PGNY

Verdict: Side-by-side breakdown using the Bull Rankings model. ELV scored 45.1, PGNY scored 67.0 — PGNY leads.
Compare another set
ELV
Elevance Health, Inc.
Healthcare Plans · Quality-Growth
45.1
$412.70 · $89.5B
fundamentals as of
Score gap
21.9
PGNY leads
PGNY
Progyny, Inc.
Healthcare Plans · Quality-Growth
67
$27.93 · $2.1B
fundamentals as of
  • CheapestELV17.8x
  • Fastest growthELV+12.6%
  • Strongest balance sheetPGNY0.06
  • Highest qualityPGNY86 / 100
  • Largest discount to fair valueELV-36%
THE BULL RANKINGS SCORECARD45.1/ 100 · BULL SCOREPEER MEDIANQUALITY54.6GROWTH64.9VALUE25.8
THE BULL RANKINGS SCORECARD67.0/ 100 · BULL SCOREPEER MEDIANQUALITY86.1GROWTH61.7VALUE56.5
ELVPGNYQuality54.686.1Growth64.961.7Value25.856.5
cheap & fastrevenue growth →← cheaper (lower multiple)-4%23%13x35xELVPGNY

Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.

FCFELV$6.3bPGNY$178m
RevELV+12.6%PGNY+5.5%
D/EELV0.69PGNY0.06
P/EELV17.8xPGNY30.4x
ELV
stronger →← stronger
PGNY
55
Qualityreturns · margins · balance sheet
86
65
Growthrevenue & earnings expansion
62
26
Valuevaluation vs sector peers
57
PGNY is stronger on 2 of 3 pillars.
ELV
PGNY
$6.3bB+
FCF
$178mC
+12.6%B+
Rev
+5.5%C+
0.69C+
D/E
0.06A-
17.8xA-
P/E
30.4xB
—
PEG
2.69C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
ELV
PGNY
36% below
Price vs fair valuelower is cheaper
30% below
~-3%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~-1%/yr
+43%
1-yr DCF upside
+30%
+56%
5-yr DCF upside
+43%
+77%
10-yr DCF upside
+65%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
ELV
Why this score
  • Buying back stock
PGNY
Why this score
  • Buying back stock
  • Durable high returns
ELVElevance Health, Inc.
Healthcare Plans · $412.70 · beta 0.71
Why now
Healthcare Plans · market cap $89.5b. 5% off the 52-week high of $436.24. Revenue growing +13%, comfortably above the S&P median. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $451.48 (implying +9% upside).
Moat
ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 127% of net income — earnings translate cleanly into cash. $89.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 2.5% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
PGNYProgyny, Inc.
Healthcare Plans · $27.93 · beta 1.02
Why now
Healthcare Plans · market cap $2.1b. 16% off the 52-week high of $33.06. 12 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $34.42 (implying +23% upside).
Moat
ROE 17% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income, mostly because of stock-based pay ($107m) — a real cost to shareholders, paid in shares rather than cash.
Risk
Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where ELV and PGNY diverge

On the headline score the gap is 21.9 points in favor of PGNY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.

Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.

Common questions

Is PGNY or ELV the better stock?

PGNY scores higher: PGNY 67.0, ELV 45.1 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.

Where do PGNY and ELV differ most?

The widest gap is quality, where PGNY leads by 32 points on the 0–100 pillar scale. Neither name sweeps: they trade the lead across the three pillars, so the comparison is a trade-off rather than one being better on every measure.

How are PGNY and ELV scored?

Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.

How current is this comparison?

The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.